Last reviewed · How we verify

NCT06336694

A Deep Learning Radiomics Model for Predicting Occult Peritoneal Metastases of Pancreatic Adenocarcinoma

Completed Last updated 29 March 2024
What this trial tests

trial testing surgery or diagnostic staging laparoscopy in Pancreatic Neoplasms in 302 participants. Completed in 30 July 2023.

Timeline
1 January 2021
Primary endpoint
31 October 2022
30 July 2023

Quick facts

Lead sponsorFirst Affiliated Hospital, Sun Yat-Sen University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment302
Start date1 January 2021
Primary completion31 October 2022
Estimated completion30 July 2023
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

First Affiliated Hospital, Sun Yat-Sen University

Who can join

18 and older, any sex, with Pancreatic Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Occult peritoneal metastases (OPM) in patients with pancreatic ductal adenocarcinoma (PDAC) are frequently overlooked during imaging. We aimed to develop and validate a CT-based deep learning-based radiomics (DLR) model with clinical-radiological characteristics to identify OPM in patients with PDAC before treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Pancreatic Neoplasms

Currently open trials in the same condition.

Other First Affiliated Hospital, Sun Yat-Sen University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06336694.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing